Cargando…
B cell-targeted therapies in autoimmunity: rationale and progress
B cells are recognized as main actors in the autoimmune process. Autoreactive B cells can arise in the bone marrow or in the periphery and, if not properly inhibited or eliminated, can lead to autoimmune diseases through several mechanisms: autoantibody production and immune complex formation, cytok...
Autores principales: | Fiorina, Paolo, Sayegh, Mohamed H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Biology Reports Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924700/ https://www.ncbi.nlm.nih.gov/pubmed/20948646 http://dx.doi.org/10.3410/B1-39 |
Ejemplares similares
-
Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes
por: Fiorina, Paolo, et al.
Publicado: (2008) -
GABAergic System in β-Cells: From Autoimmunity Target to Regeneration Tool
por: Fiorina, Paolo
Publicado: (2013) -
Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases
por: Alonso-Ramirez, Ruby, et al.
Publicado: (2010) -
Antioxidant Therapy in Cancer: Rationale and Progress
por: Luo, Maochao, et al.
Publicado: (2022) -
Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
por: Mei, Henrik E, et al.
Publicado: (2012)